Fesoterodine
Fesoterodine
Chemical compound
Fesoterodine (INN, used as the fumarate under the brand name Toviaz) is an antimuscarinic drug developed by Schwarz Pharma AG to treat overactive bladder syndrome (OAB).[1] It was approved by the European Medicines Agency in April 2007,[2] the US Food and Drug Administration on October 31, 2008 [3] and Health Canada on February 9, 2012.[4]
Fesoterodine is a prodrug. It is broken down into its active metabolite, desfesoterodine, by plasma esterases.